Illumina loses challenge to block EU antitrust probe into $8B Grail buyout
Fighting to push its $8 billion acquisition of Grail past European regulators, Illumina suffered a key setback Wednesday when an EU court ruled an antitrust probe into the buyout can proceed.
Illumina was challenging the inquiry after the EU objected to the acquisition over concerns it would concentrate most available genetic sequencing tests under one roof. The company has said it would appeal the ruling to Europe’s highest court, Reuters reported, but the bloc’s antitrust group may not wait for that process — which could take years — to wrap up before deciding whether to block the deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.